Basic Information
Bevespi Aerosphere
Regulatory Information
EMEA/H/C/004245
Authorised
December 18, 2018
October 18, 2018
8
December 3, 2024
Company Information
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Overview Summary
Bevespi Aerosphere is a medicine used in adults to relieve the symptoms of chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Bevespi Aerosphere is used for maintenance (regular) treatment. It contains the active substances glycopyrronium bromide and formoterol.